Premium
Application of 99m Tc labeled chimeric Fab fragments of monoclonal antibody A7 for immunoscintigraphy of pancreatic carcinoma
Author(s) -
Otsuji Eigo,
Matsumura Hiroomi,
Okamoto Kazuma,
Toma Atsushi,
Kuriu Yoshiaki,
Ichikawa Daisuke,
Hagiwara Akeo,
Yamagishi Hisakazu
Publication year - 2003
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.10311
Subject(s) - immunoscintigraphy , monoclonal antibody , carcinoma , spleen , epithelioma , microbiology and biotechnology , kidney , medicine , pancreas , antibody , pancreatic disease , pathology , radioimmunotherapy , immunology , biology
Background One of the reasons for the poor prognosis of pancreatic carcinoma is the difficulty of obtaining an early diagnosis of pancreatic carcinoma. One possibility is the application of radioimmunoscintigraphy using radiolabeled monoclonal antibodies (Mabs). Methods We labeled chimeric (human/mouse) Fab fragments of Mab A7 (chA7Fab) with 99m Tc and examined the distribution of 99m Tc‐labeled chA7Fab in nude mice bearing human pancreatic carcinoma. Results The tumor accumulation of 99m Tc‐labeled chA7Fab was larger than that of 99m Tc‐labeled A7 from 2 to 6 hr after injection. 99m Tc‐labeled chA7Fab disappeared from blood more rapidly than 99m Tc‐labeled A7. For all resected normal tissues except kidney, the accumulation of 99m Tc‐labeled chA7Fab was low and similar to that of 99m Tc‐labeled A7. Conclusions Because the half‐life of 99m Tc is short (6 hr), chA7Fab, which accumulates rapidly in tumors, may be a better carrier of 99m Tc than intact Mab A7. J. Surg. Oncol. 2003;84:160–165. © 2003 Wiley‐Liss, Inc.